"The in vivo studies are striking in that even a s

"The in vivo studies are striking in that even a single dose of C4 in a standard immunocompromised, neutropenic mouse model of invasive candidiasis was sufficient to reduce kidney burden to below the level found at the time of drug injection, a greater than 3-log reduction. This is an efficacy greater than some of the most recent echinocandins44. This further demonstrates that even in vivo C4 is acting as a fungicidal agent, rather than through a fungistatic mechanism. Further, a daily administration of either 10 or 15?mg/kg of C4 for four days was sufficient to prevent mortality in this model. Even at 17 days post infection with drug administration, there was no observable evidence of adverse reaction to C4, nor were there visible signs of persistence of the infection (not shown). To the contrary, after four days treatment there was significant weight gain in the treated animals."


"Studies conducted by researchers showed that CTIX-1502 (referred to as C4), a Host Defense Protein (HDP) mimic, exhibited potent, dose-dependent in vitro and in vivo activity against numerous fluconazole-resistant strains of C. albicans. Rapid membrane disruption in response to CTIX-1502 was observed. Additional lab work has since revealed the anti-fungal exhibited even greater potency when tested against a Candida species now considered to be a fungal “Superbug” that a recent Forbes article called an emerging global threat.


http://www.ipharminc.com/new-blog/2017/9/25/i...l-superbug

https://www.nature.com/articles/s41598-017-04462-6